RIR and the Impact on Clinical Outcomes in Patients Undergoing PCI

hsCRP Clinical Trial

Official title: A Prospective Study of Residual Inflammatory Risk and the Impact on Clinical Outcomes in Patients Undergoing Percutaneous Coronary Interventions

Status Recruiting

Clinical Trial Summary

Coronary heart disease (CAD) is caused by myocardial ischemia, hypoxia or necrosis due to coronary artery stenosis, spasm or obstruction. Although standard drug therapy can greatly improve the prognosis of patients with CAD after percutaneous coronary interventions (PCI), these patients are still at high risk of major adverse cardiovascular events (MACE).

At present, the concept of residual inflammation risk (RIR) has aroused widespread concern. RIR is an important independent risk in patients with CAD. Foreign studies indicate that hsCRP ≥ 2mg / L is the definition standard of RIR in CAD. In China, there is no defined value of RIR for patients undergoing PCI, and the incidence of RIR has not been investigated clearly. At the same time, the impact of dynamic changes of hsCRP on MACE in PCI population needs to be further explored. Therefore, in this study, we plan to recruit patients undergoing PCI, and observe the impact of RIR by serial hsCRP measurements on the prognosis of these patients followed up for 5 years.

Clinical Trial Description

Serial hsCRP measurements with ≥ 4 weeks between both measurements are defined in this analysis. Time-to-event is measured from first hsCRP measurement. ;

Related Conditions & MeSH terms

• hsCRP

• NCT number: NCT05131750
• Study type: Observational
• Source: Wuhan Union Hospital, China
• Contact: Miao Yu, Doctor
• Phone: +8613995562434
• Email: yumiaodavid@126.com
• Status: Recruiting
• Start date: May 6, 2021
• Completion date: December 31, 2026